Arrowstreet Capital Limited Partnership Sells 7,907,218 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Arrowstreet Capital Limited Partnership lessened its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 53.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,990,407 shares of the company's stock after selling 7,907,218 shares during the quarter. Arrowstreet Capital Limited Partnership owned about 0.62% of Teva Pharmaceutical Industries worth $154,069,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Janus Henderson Group PLC boosted its position in shares of Teva Pharmaceutical Industries by 7,945.2% in the third quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company's stock valued at $86,350,000 after acquiring an additional 4,732,374 shares during the period. Clal Insurance Enterprises Holdings Ltd raised its stake in Teva Pharmaceutical Industries by 12.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after purchasing an additional 4,418,961 shares during the last quarter. Todd Asset Management LLC bought a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $58,243,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Teva Pharmaceutical Industries by 237.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company's stock valued at $60,863,000 after buying an additional 2,376,668 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of Teva Pharmaceutical Industries by 10.0% in the third quarter. State Street Corp now owns 19,500,683 shares of the company's stock valued at $351,402,000 after buying an additional 1,778,268 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Remove Ads

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA traded down $1.06 on Friday, hitting $13.79. The stock had a trading volume of 5,545,096 shares, compared to its average volume of 9,689,594. The company has a market capitalization of $15.63 billion, a price-to-earnings ratio of -9.54, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The firm's 50 day moving average price is $16.67 and its 200-day moving average price is $18.04. Teva Pharmaceutical Industries Limited has a twelve month low of $12.51 and a twelve month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Analyst Ratings Changes

TEVA has been the topic of a number of research reports. Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. Bank of America decreased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Friday. Barclays decreased their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. Finally, UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of "Moderate Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.